Treatment of refractory adult‐onset pityriasis rubra pilaris with TNF‐alpha antagonists: a case series
Authors:
- 2 July 2010
- journal article
- case report
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 24 (8) , 881-884
Abstract
Background Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis with frequent clinical presentation as erythroderma. Conventional systemic treatment is often unsatisfactory and limited by long‐term toxicity. The use of tumour necrosis factor (TNF) antagonists has been reported previously in single cases, but lacking long‐term follow‐up or comparison between different biological agents.Objectives To assess the long‐term efficacy and safety of TNF‐alpha antagonist, infliximab and etanercept, either in monotherapy or in combination therapy of severe, refractory adult‐onset PRP.Methods Seven patients of adult‐onset PRP, six newly diagnosed type‐I and 1 type‐II, which were resistant or ineligible to conventional systemic treatment, received a single course of infliximab or etanercept therapy, alone or in combination with low‐dose acitretin (>0.25 mg/kg/daily). After complete remission and treatment discontinuation, a follow‐up period of 12 months was evaluated for relapses.Results Six patients obtained complete remission after a single course of anti‐TNF‐alpha therapy: mean therapy duration was 19.3 weeks (range 6–48 weeks). All patients obtained significant clearing (>75% of body surface area) of skin lesions at week 12. Two patients with marked keratoderma developed localized disease recurrence during treatment. During follow‐up, only a single patient, affected by type II PRP, had disease relapse.Conclusions Both TNF‐alpha antagonists proved successful for the treatment of refractory, adult‐onset PRP, yielding complete and persistent clinical responses in type‐I PRP. Infliximab was associated with a more rapid onset of action, while treatment duration was comparable with etanercept. PRP type II warranted long‐term therapy and showed relapse after drug discontinuation.Keywords
This publication has 13 references indexed in Scilit:
- Pityriasis rubra pilaris type 1 spontaneously resolving after 20 yearsClinical and Experimental Dermatology, 2009
- Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapyJournal of the American Academy of Dermatology, 2008
- Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximabJournal of the European Academy of Dermatology and Venereology, 2007
- Successful use of etanercept in type I pityriasis rubra pilarisBritish Journal of Dermatology, 2007
- Pityriasis Rubra Pilaris Successfully Treated with InfliximabActa Dermato-Venereologica, 2007
- Acute Juvenile Pityriasis Rubra Pilaris: A Superantigen Mediated Disease?Pediatric Dermatology, 2001
- Pityriasis rubra pilarisInternational Journal of Dermatology, 1999
- Changing forms of juvenile pityriasis rubra pilaris-a case reportClinical and Experimental Dermatology, 1994
- Pityriasis rubra pilaris: The problem of its classificationJournal of the American Academy of Dermatology, 1992
- Pityriasis rubra pilaris and retinol-binding proteinBritish Journal of Dermatology, 1981